The short answer
OASIS 2 was a randomised clinical trial of oral semaglutide in an East Asian population with overweight or obesity, with or without type 2 diabetes, published by Kadowaki and colleagues in JAMA Internal Medicine in October 2025.
Key facts
- Trial
- OASIS 2
- Compound
- Oral semaglutide
- Population
- East Asian, overweight or obesity
- With or without
- Type 2 diabetes
- Published
- JAMA Intern Med, 1 October 2025
- PMID
- 40758358
Why population-specific trials exist
Not as a formality. Body composition at a given body mass index differs between populations, and the BMI thresholds defining overweight and obesity are set lower in several East Asian countries because metabolic risk appears at lower BMI. A trial recruiting to different thresholds is studying a different population, not the same one relabelled.
What differs pharmacologically
Body weight itself, which affects volume of distribution and therefore exposure at a fixed dose. Baseline body composition. Background diet and the prevalence of comorbidities. Genetic variation in drug-metabolising enzymes for compounds that depend on them. Each can shift the dose-response relationship without anything about the drug changing.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
Why an oral formulation raises the stakes
Oral semaglutide depends on the absorption enhancer SNAC and on strict administration conditions. A fasting window and a defined volume of water. Anything affecting gastric conditions affects absorption, and absorption of this formulation is variable to begin with. A route that fragile is more sensitive to population differences than a subcutaneous injection.
What including and excluding diabetes achieves
Recruiting participants with and without type 2 diabetes allows the same trial to describe both, and weight response has consistently been smaller in people with diabetes across this drug class. Reporting them together without separating them would produce an average describing neither group.
Why this matters for reading any headline figure
A weight-reduction percentage is a property of a trial, not of a molecule. Population, baseline weight, duration, diabetes status and estimand all move it. Two honest trials of the same drug can report meaningfully different numbers, and neither is wrong.
What it does not concern
Research material. OASIS 2 studied a licensed medicine in a defined population under clinical supervision. Nothing supplied here is semaglutide, in any formulation, or an alternative to it.
Frequently asked questions
Why run a separate trial in an East Asian population?
BMI thresholds for overweight and obesity are set lower in several East Asian countries because metabolic risk appears at lower BMI, so the population differs.
Why does the oral formulation make this more important?
It depends on the SNAC absorption enhancer and strict administration conditions, so it is more sensitive to anything affecting gastric conditions.
Does diabetes status change the weight result?
Yes. Weight response has consistently been smaller in people with type 2 diabetes across this drug class.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedKadowaki T et al., Oral Semaglutide in an East Asian Population With Overweight or Obesity: The OASIS 2 Randomized Clinical Trial. JAMA Intern Med 2025 (PMID 40758358)pubmed.ncbi.nlm.nih.gov
- PubMedWharton S et al., STEP UP. Lancet Diabetes Endocrinol 2025 (PMID 40961952)pubmed.ncbi.nlm.nih.gov
- PubChemPubChem · Semaglutide (CID 56843331)pubchem.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- The Question Underneath the Lean Mass DebateAll weight loss costs fat-free mass, including diet and surgery. The real questions are whether incretins cost more, and whether it has functional consequences.
- What Fat-Free Mass Actually ContainsBone, organs, water and blood-forming tissue all sit inside the fat-free compartment. Treating the number as a muscle measurement is a category error.
- The Method Determines the NumberDXA and bioimpedance do not agree, and they disagree most during active weight change. Why a lean mass percentage is partly a property of the instrument.
- Blocking the Brake on Muscle GrowthMyostatin restrains muscle growth through activin type II receptors. Blocking them preserves muscle - and a 2024 paper reports it enhances fat loss too.
- Taldefgrobep Alfa: A Second Route Into the Same PathwayA myostatin-directed agent now in a Phase 2 obesity trial. Why more than one compound is targeting the same pathway from different angles.